294 related articles for article (PubMed ID: 16443556)
1. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
Cho HI; Hong YS; Lee MA; Kim EK; Yoon SH; Kim CC; Kim TG
Int J Hematol; 2006 Jan; 83(1):66-73. PubMed ID: 16443556
[TBL] [Abstract][Full Text] [Related]
2. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
4. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases.
Takahashi E; Asano N; Li C; Tanaka T; Shimada K; Shimada S; Yoshino T; Kojima M; Hara K; Eimoto T; Nakamura S
Histopathology; 2008 Apr; 52(5):585-96. PubMed ID: 18370955
[TBL] [Abstract][Full Text] [Related]
5. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
7. Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.
Ohshima K; Liu Q; Koga T; Suzumiya J; Kikuchi M
Virchows Arch; 2002 Apr; 440(4):425-35. PubMed ID: 11956825
[TBL] [Abstract][Full Text] [Related]
8. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage.
Chiang AK; Chan AC; Srivastava G; Ho FC
Int J Cancer; 1997 Nov; 73(3):332-8. PubMed ID: 9359478
[TBL] [Abstract][Full Text] [Related]
9. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
10. Intestinal T-cell and natural killer-cell lymphomas in Taiwan with special emphasis on 2 distinct cellular types: natural killer-like cytotoxic T cell and true natural killer cell.
Tung CL; Hsieh PP; Chang JH; Chen RS; Chen YJ; Wang JS
Hum Pathol; 2008 Jul; 39(7):1018-25. PubMed ID: 18482744
[TBL] [Abstract][Full Text] [Related]
11. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
14. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
15. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
Savoldo B; Huls MH; Liu Z; Okamura T; Volk HD; Reinke P; Sabat R; Babel N; Jones JF; Webster-Cyriaque J; Gee AP; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 Dec; 100(12):4059-66. PubMed ID: 12393655
[TBL] [Abstract][Full Text] [Related]
16. Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile.
Cabrera ME; Eizuru Y; Itoh T; Koriyama C; Tashiro Y; Ding S; Rey S; Akiba S; Corvalan A
J Clin Pathol; 2007 Jun; 60(6):656-60. PubMed ID: 16775124
[TBL] [Abstract][Full Text] [Related]
17. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
18. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.
Kuzushima K; Yamamoto M; Kimura H; Ando Y; Kudo T; Tsuge I; Morishima T
Clin Exp Immunol; 1996 Feb; 103(2):192-8. PubMed ID: 8565299
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases.
Schwartz EJ; Molina-Kirsch H; Zhao S; Marinelli RJ; Warnke RA; Natkunam Y
Am J Clin Pathol; 2008 Sep; 130(3):343-51. PubMed ID: 18701406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
